Print this Page

Snapshot: Regulus Therapeutics (NASDAQ: RGLS)

Regulus Therapeutics
Name: Kleanthis G. Xanthopoulos, Ph.D.
Title: President and CEO
Company: Regulus Therapeutics
Location: La Jolla, CA
Regulus Therapeutics
Social Media: @regulusrx
Year Founded: Formed in 2007 by parent companies, Isis and Alnylam, and incorporated in Delaware in 2009
Number of Employees: Approximately 60
Description: Regulus Therapeutics Inc. is a biopharmaceutical company advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.
Products or Pipeline, Phase: All programs are in preclinical development.

How would you describe the IPO funding environment?

The IPO funding environment has turned positive in the recent months and we’ve seen this first hand with our successful IPO in October.

What are the keys to a successful IPO?

Prior to considering entrance into the public arena, we believe that companies need to have the following three components of their business on solid footing:  people, strategy and finance.  The people are the foundation and backbone of a company.  A company’s strategy is fundamental to its success when considering entrance into the public arena.  The last component is finance.  Before entering the public market, a company should already be on solid financial footing in the event that the offering does not come to fruition or the company is not able to raise as much capital as they needed to get them to the next financing event.

How is this impacting the industry overall?  In California?

Recently, it seems there have been fewer life-science companies attempting to enter the public arena in California.  This year, in San Diego alone, we believe that Regulus is the only life-sciences company to successfully go public.  Because we believe that the IPO fundraising environment may be turning around, we hope to see additional life-science companies attempt to enter into the public arena in the near future.

What do you think would help strengthen the capital markets for the life science industry?

Innovation and execution on the innovation – we believe that the life-science industry needs more innovative medicines and therapies to treat patients.  And in turn, the capital markets need to be willing to back these companies providing the innovative ideas and technologies in the therapeutic areas with high unmet medical need.

Permanent link to this article: